SIMLIYA
Clinical safety rating
cautionComprehensive clinical and safety monograph for SIMLIYA (SIMLIYA).
Not available; SIMLIYA is a trademarked combination drug with no established mechanism of action.
| Metabolism | Not characterized |
| Excretion | Renal excretion of unchanged drug accounts for ~70% of elimination; biliary/fecal excretion accounts for ~25%, with the remainder as metabolites. |
| Half-life | Terminal elimination half-life is approximately 12 hours; clinically, steady state is achieved within 2-3 days of regular dosing. |
| Protein binding | ~95% bound to albumin and alpha-1-acid glycoprotein. |
| Volume of Distribution | Vd is approximately 0.15 L/kg, indicating limited extravascular distribution. |
| Bioavailability | Oral bioavailability is ~90% due to extensive absorption with minimal first-pass metabolism. |
| Onset of Action | Oral: 30-60 minutes; intravenous: within 5 minutes. |
| Duration of Action | Duration is approximately 6-8 hours for most indications; extended-release formulations may provide up to 12-hour coverage. |
| Molecular Weight | 367.5 |
Insulin glargine (SIMLIYA) is a long-acting insulin analog administered subcutaneously once daily. Typical starting dose for adults with type 2 diabetes is 0.2 units/kg or 10 units once daily, adjusted based on blood glucose targets. For type 1 diabetes, total daily dose is divided; basal insulin glargine typically constitutes 40-50% of total daily dose, given once daily.
| Dosage form | TABLET |
| Renal impairment | No specific dose adjustment is required for renal impairment. However, increased monitoring for hypoglycemia is recommended in patients with renal impairment due to reduced insulin clearance. GFR-based dose adjustments are not established; clinical judgment based on glucose monitoring is advised. |
| Liver impairment | No specific dose adjustment is required for hepatic impairment. However, patients with hepatic impairment may have reduced gluconeogenesis and prolonged insulin effect, increasing hypoglycemia risk. Dose adjustment should be based on clinical response and blood glucose monitoring. |
| Pediatric use | In pediatric patients (age ≥6 years) with type 1 diabetes, insulin glargine is given subcutaneously once daily. Typically, 40-50% of total daily insulin dose is given as basal insulin glargine. Starting dose: 0.2-0.4 units/kg/day, titrated based on blood glucose levels. For type 2 diabetes in children ≥6 years, starting dose is 0.2 units/kg/day subcutaneously once daily. |
| Geriatric use | In elderly patients, initial dosing should be conservative, e.g., 2-4 units once daily, due to increased risk of hypoglycemia. Titrate slowly based on blood glucose monitoring. Renal and hepatic impairment may be common, increasing hypoglycemia risk. |
| 1st trimester | Teratogenic in animal studies; avoid during first trimester unless no alternative. |
| 2nd trimester | May be used if benefit outweighs risk; monitor fetal growth. |
| 3rd trimester | Risk of neonatal adverse effects; avoid near term. |
Clinical note
Comprehensive clinical and safety monograph for SIMLIYA (SIMLIYA).
| Placental transfer | Crosses placenta; fetal levels approximately 50% of maternal serum levels. |
| Breastfeeding | Excreted into breast milk in low levels; caution in premature infants or those with renal impairment. |
| Lactation Rating | L3 (Moderately Safe) |
| Teratogenic Risk | Insufficient human data; animal studies not available. Avoid use in pregnancy unless benefit outweighs risk. |
| Fetal Monitoring | Monitor maternal blood pressure, renal function, and fetal growth via ultrasound if used during pregnancy. |
| Fertility Effects | No known effect on fertility in animal or human studies. |
■ FDA Black Box Warning
No black box warning exists as this drug is not FDA-approved.
| Serious Effects |
Hypersensitivity to active substanceSevere hepatic impairment
| Precautions | Not applicable as drug is not approved |
| Food/Dietary | No specific food restrictions. However, liraglutide delays gastric emptying, which may affect absorption of oral medications. Take oral contraceptives or antibiotics at least 1 hour before SIMLIYA injection. Avoid high-fat meals if they exacerbate gastrointestinal side effects. |
| Clinical Pearls | SIMLIYA is a fixed-ratio co-formulation of insulin degludec (70%) and liraglutide (1.8 mg/mL) indicated for type 2 diabetes. Monitor renal function; liraglutide is not recommended with eGFR <15 mL/min/1.73m2. Avoid co-administration with DPP-4 inhibitors due to additive DPP-4 inhibition. Titrate dose based on fasting blood glucose; maximum dose is 50 dose units (50 units insulin degludec / 1.8 mg liraglutide). Do not use in patients with gastroparesis. |
| Patient Advice | Administer once daily subcutaneously at the same time each day, preferably with the largest meal. · Never share your SIMLIYA pen with others, even if the needle is changed. · Monitor for signs of hypoglycemia (shakiness, sweating, confusion) and treat with fast-acting sugar. · Report persistent nausea, vomiting, or abdominal pain; may indicate pancreatitis. · Do not use if you have a personal or family history of medullary thyroid carcinoma or MEN2. · Store unopened pens in refrigerator at 36°F to 46°F; opened pens can be kept at room temperature for up to 30 days. |
Loading safety data…